AMCP Market Insights: Examining the current and future state of hemophilia B gene therapy in managed care

New technologies, such as nonreplacement and gene therapies, have emerged to mitigate the treatment burden and other limitations associated with factor replacement therapy for hemophilia B. Gene therapies, in particular, show promise as potential cures; however, they pose unique challenges to managed care pharmacy and warrant guidance for payers. AMCP Market Insights virtually convened an expert panel of managed care stakeholders in June 2026 to gather this guidance through examining the current and future state of hemophilia B gene therapy. This article provides a qualitative summary of the panel discussion along with key insights and suggested payer practices meant to support informed coverage decisions and guide future work such as collaboration, research, and advocacy. Key insights underscore that the current treatment paradigm requiring factor replacement therapy for hemophilia B is suboptimal as it is associated with adherence limitations and cost unpredictability; to improve its value, participants suggest payers direct patients with hemophilia to receive care in hemophilia treatment centers, provide high-touch, hemophilia-specific care management, and designate specialized reviewers for hemophilia-related coverage requests. Additional findings are that hemophilia B gene therapy has clinical value, but effective delivery requires multiple solutions involving collaboration among stakeholders to overcome both organizational and systemic challenges such as low usage and inadequate funding methods. Essential to effective delivery is evidence generation to better understand patient and provider decision-making, to determine safety and effectiveness in subpopulations, to assess long-term durability, and to evaluate cost outcomes. Also essential is improving the ability to implement alternative financing methods, which participants suggest could be done with enhanced outcomes tracking infrastructure and deeper analysis of internal payer data to assess cost-effectiveness and determine value.

Authors

Institutions

Publication Details

Journal
Journal of Managed Care & Specialty Pharmacy
Published
2026-11-17
DOI
https://doi.org/10.18553/jmcp.2026.32.12-b.s1
Primary Topic
Hemophilia Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

AMCP Market Insights: Examining the current and future state of hemophilia B gene therapy in managed care

Rachael Prusi, Christina Barrington, Bridget M. Flavin, Christopher Walsh et al.
3 links
Journal of Managed Care & Specialty Pharmacy
Hemophilia Treatment and Research
article

AMCP Market Insights: Examining the current and future state of hemophilia B gene therapy in managed care

Rachael Prusi, Christina Barrington, Bridget M. Flavin, Christopher Walsh, Terry Richardson, Cody Olsen, Charles Dragovich, Jonathan James, AJ Steil
article en

Abstract

New technologies, such as nonreplacement and gene therapies, have emerged to mitigate the treatment burden and other limitations associated with factor replacement therapy for hemophilia B. Gene therapies, in particular, show promise as potential cures; however, they pose unique challenges to managed care pharmacy and warrant guidance for payers. AMCP Market Insights virtually convened an expert panel of managed care stakeholders in June 2026 to gather this guidance through examining the current and future state of hemophilia B gene therapy. This article provides a qualitative summary of the panel discussion along with key insights and suggested payer practices meant to support informed coverage decisions and guide future work such as collaboration, research, and advocacy. Key insights underscore that the current treatment paradigm requiring factor replacement therapy for hemophilia B is suboptimal as it is associated with adherence limitations and cost unpredictability; to improve its value, participants suggest payers direct patients with hemophilia to receive care in hemophilia treatment centers, provide high-touch, hemophilia-specific care management, and designate specialized reviewers for hemophilia-related coverage requests. Additional findings are that hemophilia B gene therapy has clinical value, but effective delivery requires multiple solutions involving collaboration among stakeholders to overcome both organizational and systemic challenges such as low usage and inadequate funding methods. Essential to effective delivery is evidence generation to better understand patient and provider decision-making, to determine safety and effectiveness in subpopulations, to assess long-term durability, and to evaluate cost outcomes. Also essential is improving the ability to implement alternative financing methods, which participants suggest could be done with enhanced outcomes tracking infrastructure and deeper analysis of internal payer data to assess cost-effectiveness and determine value.

Journal of Managed Care & Specialty PharmacyVol. 32(12-b Suppl)
Marquette General Hospital (US), Catholic Charities (US), Five Prime Therapeutics (United States) (US), Minnesota Department of Health (US), Icahn School of Medicine at Mount Sinai (US)
Good health and well-being
Hemophilia Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon